Corpus overview


MeSH Disease

Pneumonia (960)

Disease (453)

Infections (447)

Coronavirus Infections (276)

Death (205)

Human Phenotype

Pneumonia (1049)

Fever (168)

Cough (135)

Respiratory distress (79)

Hypertension (64)


    displaying 11 - 20 records in total 1091
    records per page

    Evaluation of Convalescent Plasma SERO versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

    Authors: Elena Diago-Sempere; Jose Luis Bueno; Aranzazu Sancho-Lopez; Elena Munez-Rubio; Ferran Torres; Rosa Malo de Molina; Ana Fernandez-Cruz; Isabel Salcedo De Diego; Ana Velasco-Iglesias; Concepcion Payares Herrera; Inmaculada Casas Flecha; Cristina Avendano-Sola; Rafael Duarte Palomino; Antonio Ramos-Martinez; Belen Ruiz-Antoran

    doi:10.1101/2020.07.31.20165720 Date: 2020-08-04 Source: medRxiv

    Background: COVID-19 is a respiratory disease MESHD caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma SERO (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections MESHD (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma SERO in adult TRANS patients with severe COVID-19 pneumonia MESHD pneumonia HP. Methods/Design: The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The protocol has been prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. The study has been planned to include 278 adult TRANS patients hospitalized with severe COVID-19 infection MESHD not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to categories 5, 6 or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion: This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma SERO for the treatment of adult TRANS patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease MESHD. Trial registration: Trial registration at; Registration Number: NCT04345523;; Registered on 30 March, 2020. First posted date: April 14, 2020. Keywords: COVID-19, randomized, controlled trial, protocol, convalescent plasma SERO (CP), antibodies SERO.

    A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection MESHD

    Authors: Hongbo Chen; Zhongping Xie; Runxiang Long; Shengtao Fan; Heng Li; Zhanlong He; Kanwei Xu; Yun Liao; Lichun Wang; Ying Zhang; Xueqi Li; Xingq Dong; Tangwei Mou; Xiaofang Zhou; Yaoyun Yang; Lei Guo; Jianbo Yang; Huiwen Zheng; Xingli Xu; Jing Li; Yan Liang; Dandan Li; Zhimei Zhao; Chao Hong; Heng Zhao; Guorun Jiang; Yanchun Che; Fengmei Yang; Yunguang Hu; Xi Wang; Jing Pu; Kaili Ma; Chen Chen; Weiguo Duan; Dong Shen; Hongling Zhao; Ruiju Jiang; Xinqiang Deng; Yan Li; Hailian Zhu; Jian Zhou; Li Yu; Mingjue Xu; Huijuan Yang; Li Yi; Zhenxin Zhou; Jiafang Yang; Nan Duan; Huan Yang; Wangli Zhao; Wei Yang; Changgui Li; Longding Liu; Qihan Li

    doi:10.1101/2020.08.04.235747 Date: 2020-08-04 Source: bioRxiv

    With the relatively serious global epidemic outbreak of SARS-CoV-2 infection MESHD, public concerns focus on not only clinical therapeutic measures and public quarantine for this disease MESHD but also the development of vaccines. The technical design of our SARS-CoV-2 inactivated vaccine provides a viral antigen that enables the exposure of more than one structural protein based upon the antibody SERO composition of COVID-19 patients convalescent serum SERO. This design led to valid immunity with increasing neutralizing antibody SERO titers and a CTL response detected post-immunization of this vaccine by two injections in rhesus macaques. Further, this elicited immunoprotection in macaques enables not only to restrain completely viral replication in tissues of immunized animals, compared to the adjuvant control and those immunized by an RBD peptide vaccine, but also to significantly alleviate inflammatory lesion in lung tissues in histo-pathologic detection, compared to the adjuvant control with developed interstitial pneumonia MESHD pneumonia HP. The data obtained from these macaques immunized with the inactivated vaccine or RBD peptide vaccine suggest that immunity with a clinically protective effect against SARS-CoV-2 infection MESHD should include not only specific neutralizing antibodies SERO but also specific CTL responses against at least the S and N antigens.

    Self-Reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China

    Authors: Jia Song; Yi-Ke Deng; Hai Wang; Zhi-Chao Wang; Bo Liao; Jin Ma; Chao He; Li Pan; Yang Liu; Isam Alobid; De-Yun Wang; Ming Zeng; Joaquim Mullol; Zheng Liu

    doi:10.21203/ Date: 2020-08-03 Source: ResearchSquare

    Background: Last December 2019, a cluster of viral pneumonia MESHD pneumonia HP cases identified as coronavirus disease MESHD 2019 (COVID-19), was reported in Wuhan, China. We aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss of smell and taste, as well as their presentation as the first symptom of the disease MESHD and their association with the severity of COVID-19.Methods: In this retrospective study, 1,206 laboratory-confirmed COVID-19 patients were included and followed-up by telephone call one month after discharged from Tongji Hospital, Wuhan. Demographic data, laboratory values, comorbidities, symptoms, and numerical rating scale scores (0-10) of nasal symptoms were extracted from the hospital medical records, and confirmed or reevaluated by the telephone follow-up. Results: From COVID-19 patients (N = 1,172) completing follow-up, 199 (17%) subjects had severe COVID-19 and 342 (29.2%) reported nasal symptoms. The most common nasal symptom was loss of taste (20.6%, median score = 6), while 11.4% had loss of smell (median score = 5). The incidence of nasal symptom including loss of smell and loss of taste as the first onset symptom TRANS was <1% in COVID-19 patients. Loss of smell or taste scores showed no correlation with the scores of other nasal symptoms. Loss of taste scores, but not loss of smell scores, were significantly increased in severe vs. non-severe COVID-19 patients. Interleukin (IL)-6 and lactose dehydrogenase (LDH) serum SERO levels positively correlated with loss of taste scores. About 80% of COVID-19 patients recovered from smell and taste dysfunction in 2 weeks.Conclusions: In the Wuhan COVID-19 cohort, only 1 out of 10 hospital admitted patients had loss of smell while 1 out 5 reported loss of taste which was associated to severity of COVID-19. Most patients recovered smell and taste dysfunctions in 2 weeks.

    SARS-CoV-2 A Relation with Other Acute Respiratory Tract Infectious (ARTI) Diseases MESHD: A Short Communication

    Authors: HAKANI SYMPLI

    id:10.20944/preprints202008.0065.v1 Date: 2020-08-03 Source:

    The short study implicates few basic similarities of COVID-19 such as diseases MESHD origination, symptoms, diagnosis with other relatable viral diseases MESHD viz SARS-CoV, common Flu, pneumonia MESHD pneumonia HP etc. In the present situation, other viral diseases MESHD are frequently chaotic and misled with COVID-19 disease MESHD because of few clinical features similarities in signs and symptoms MESHD and also due to lack of specific diagnostic test. To avoid unnecessary suspects, quarantines of false positive results and to prevent the spread of COVID-19 diseases MESHD, the scientific technical research field are highly encourage to implement an efficient, rapid and sophisticated superior test for early stages of infection MESHD detection. It will be significantly convenient for physician, laboratory technicians and most importantly the common population facing a psychological disturbance.

    Neutrophil Percentage and Neutrophil-to-Monocyte Ratio as Independent Risk Factors in the Severity of COVID-19

    Authors: Fei Peng; Si Lei; Chenfang Wu; Bo Yu; Yanjun Zhong; Shangjie Wu

    doi:10.21203/ Date: 2020-08-02 Source: ResearchSquare

    BackgroundInflammation plays an important role in progression of the various viral pneumonia MESHD pneumonia HP containing COVID-19, severe inflammatory responses could lead to an imbalance of immune response. The purpose of this study was to explore the possibility of the white blood SERO count, neutrophil percentage, neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) at admission to reflect the clinical severity in patients with COVID‐19.MethodsClinical and laboratory data of adult TRANS COVID-19 patients in Changsha, China, were collected and analyzed on admission. A logistic regression model was adopted to analyze the association between the disease MESHD severity and related risk factors. The receiver operating characteristic (ROC) curve was utilized to analyze the abilities of potential risk factors in the prediction of COVID-19 severity.ResultsCompared with non-severe patients, the severe ones had significantly higher levels of neutrophil percentage (74.9% vs. 62.1%; P < 0.001), NLR (4.1 vs. 2.1; P < 0.001) and NMR (12.4 vs. 8.0; P < 0.001). A regression analysis showed that neutrophil percentage (OR,1.113; 95% CI, 1.020-1.213; P=0.016) and NMR (OR, 1.110; 95% CI, 1.002-1.230; P = 0.046) were significantly associated with severity of COVID-19 patients. ROC curve showed that the area under the curves of neutrophil percentage, NMR and the combination of them were 0.842 (95% confidence interval (CI), 0.782-0.902), 0.790 (95% CI, 0.710-0.871) and 0.851 (95% CI, 0.790-0.911), respectively.ConclusionsNeutrophil percentage and NMR may act as independent risk factors in the severity of COVID-19.

    Rationale for the Use of Radiation-Activated Mesenchymal Stem Cells in Acute Respiratory Distress HP Syndrome MESHD

    Authors: Isabel Tovar Martín; Rosa Guerrero; Jesús Joaquín Lopez-Peñalver; José Expósito; José Mariano Ruiz de Almodóvar

    id:10.20944/preprints202008.0035.v1 Date: 2020-08-02 Source:

    Previously we have shown that the combination of radiotherapy with human-umbilical-cord-derived mesenchymal stem-cell therapy significantly reduces the size of the xenotumours in mice, both in the directly irradiated tumour and in the distant non-irradiated tumour or in its metastasis. We have also shown that exosomes secreted from mesenchymal stem-cells pre-irradiated with 2 Gy are quantitatively, functionally and qualitatively different from the exosomes secreted from non-irradiated mesenchymal cells and also that proteins, exosomes and microvesicles secreted by mesenchymal cells suffer a dramatic change when cells are activated or non-activated, with the amount of protein present in the exosomes of the pre-irradiated cells being 1.5-fold times greater compared to those from non-irradiated cells. This finding correlates with a dramatic increase in the anti-tumour activity of the exosomes secreted by pre-irradiated mesenchymal-cells. After the proteomic analysis of the load of the exosomes released from both irradiated and non-irradiated cells, we conclude that annexin A1 is the most important and significant difference between the exosomes released by the cells in either status. Knowing the role of annexin A1 in the control of hypoxia MESHD and inflammation MESHD which is characteristic of acute- distress-respiratory HP syndrome MESHD, we have designed a hypothetical therapeutic strategy, based on the transplantation of mesenchymal stem cells stimulated with radiation, to alleviate the symptoms of patients who, due to pneumonia MESHD pneumonia HP caused by COVID-19, require the care of an intensive care unit for patients with life-threatening conditions. With this hypothesis, we would seek to improve the patients’ respiratory capacity and increase the expectations of their cure.

    COVID-19: Role of the Interferons

    Authors: Claudio G. Gallo; Sirio Fiorino; Giovanni Posabella; Donato Antonacci; Antonio Tropeano; Emanuele Pausini; Carlotta Pausini; Tommaso Guarniero; Marco Zancanaro

    id:202008.0018/v1 Date: 2020-08-02 Source:

    COVID-19 disease MESHD, caused by the SARS-CoV2 virus, is a potentially fatal disease MESHD that represents a serious public health and economic problem worldwide. The SARS-CoV2 virus infects the lower respiratory tract and can cause pneumonia MESHD pneumonia HP in humans. ARDS is the leading cause of death MESHD in COVID-19 disease MESHD. One of the main characteristics of ARDS is the cytokine storm, an uncontrolled systemic inflammatory response resulting from the release of pro-inflammatory cytokines and chemokines and growth factors, by immune cells. The other important aspect of the disease MESHD is represented by the involvement of the vascular organ that undergoes endothelitis. Hyperinflammation and endothelitis contribute in various ways to trigger coagulation disorders with diffuse micro thrombotic and thromboembolic phenomena. Lastly, multiple organ failure MESHD may occur (MOF). Since so far there is no approved treatment, there is an urgent need to reposition known treatments, considered safe, to be included in trials. Naturally produced interferons represent the body's first line of defense against viruses. Pharmacological forms, obtained by means of genetic recombination techniques, have long been approved and used to treat numerous pathologies. Interferons are divided into three families, within which some subfamilies are distinguishable. Only IFN-II comprises a single isoform which has completely different aspects and functions. The IFN I and III, however, each comprise different subfamilies (17 subfamilies the IFN-I and 4 subfamilies the IFN-III), share many aspects, representing the body's first antiviral response, but play different roles. The use of IFNs has been studied in two severe hCoV (Human Coronavirus) diseases MESHD, closely related to COVID-19 disease MESHD, such as SARS and MERS. Numerous in vitro and in vivo studies have been conducted, often in combination with other antivirals. The results have been controversial. The positive results in vitro and in experimental animals were often not replicable in humans. The possible positioning of these molecules in the right window of therapeutic opportunity requires that the complex dialogue between IFN, inflammasome, cytokines, pro-inflammatory chemokines, growth factors and barrier function be shed light.

    Development a quantitative segmentation model to assess the effect of comorbidity on patients with COVID-19

    Authors: Cui Zhang; Guangzhao Yang; Chunxian Cai; Zhihua Xu; Hai Wu; Youmin Guo; Zongyu Xie; Hengfeng Shi; Guohua Cheng; Jian Wang

    doi:10.21203/ Date: 2020-08-01 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19) has brought a global disaster. Quantitative lesions may provide the radiological evidence of the severity of pneumonia MESHD pneumonia HP and further to assess the effect of comorbidity on patients with COVID-19.Methods: 294 patients with COVID-19 were enrolled from February, 24, 2020 to June, 1, 2020 from six centers. Multi-task Unet network was used to segment the whole lung and lesions from chest CT images. This deep learning method was pre-trained in 650 CT images (550 in primary dataset and 100 in test dataset) with COVID-19 or community acquired pneumonia MESHD pneumonia HP and Dice coefficients in test dataset were calculated. 50 CT scans of 50 patients (15 with comorbidity and 35 without comorbidity) were random selected to mark lesions manually. The results will be compared with the automatic segmentation model. Eight quantitative parameters were calculated based on the segmentation results to evaluate the effect of comorbidity on patients with COVID-19.Results: Quantitative segmentation model was proved to be effective and accurate with all Dice coefficients more than 0.85 and all accuracies more than 0.95. Of the 294 patients, 52 (17.7%) patients were reported having at least one comorbidity, 14 (4.8%) having more than one comorbidity. Patients with any comorbidity were older (P<0.001), had longer incubation period TRANS (P<0.001), were more likely to have abnormal laboratory findings (P<0.05) and be in severity status (P<0.001). More lesions (including larger volume of lesion, consolidation and ground-glass opacity) were shown in patients with any comorbidity than patients without comorbidity (all P<0.001). The more comorbidities patients have, the poorer CT manifestation is. The median volume of lesion, consolidation and ground-glass opacity in diabetes mellitus MESHD diabetes mellitus HP group was largest among the three prevalently single comorbidity groups.Conclusions: Multi-task Unet network can make quantitative CT analysis of lesions to assess the effect of comorbidity on patients with COVID-19, further to provide the radiological evidence of the severity of pneumonia MESHD pneumonia HP. More lesions were found in CT images of cases with comorbidity. The more comorbidities patients have, the poorer CT manifestation is. 

    Risk factors for mortality in a multicenter cohort of mechanically ventilated COVID-19 patients in Belgium.

    Authors: Bernard Lambermont; Marie Ernst; Pierre Demaret; Sandrine Boccar; Vincent Fraipont; Christine Gurdebeke; Cedric Van Brussel; Manuel Quinonez; Christophe J.J. Dubois; Thierry Lemineur; Thierry Njambou; Benoit Akando; Damien Wertz; Julien Higny; Marie Thys; Nathalie Maes; Jean-Luc Canivet; Grace Kisoka; Nathalie Layios; Didier Ledoux; Paul Massion; Philippe Morimont; Sonia Piret; Sebastien Robinet; Anne-Françoise Rousseau; Patricia Wiesen; Pierre Damas; Gilles Parzibut; Thierry Sottiaux; François Lejeune; Pierre François; Julien Guntz; Laurent Jadot; Frédéric Foret; Pierre Delanaye; Benoit Misset

    doi:10.21203/ Date: 2020-08-01 Source: ResearchSquare

    Background: Considering the high mortality rate of severe Covid-19 patients, it is necessary to identify prognostic factors and therapies which could be valuable in this setting.Methods: The method consisted in a multicentric retrospective analysis in all consecutive Covid-19 patients admitted to intensive care unit (ICU) and mechanically ventilated for more than 24 hours from March 1 to April 25, 2020.Admission date, age TRANS, sex, body mass index, underlying conditions, treatments, physiological values, use of vasopressors, renal replacement therapy and extracorporeal membrane oxygenation, duration of mechanical ventilation, length of ICU stay, ICU and ventilator-free days at day 42 were collected. Primary outcome was survival. Simple and multiple time-dependent Cox regression models were used to assess the effects of factors on survival. Results: Out of 2003 patients hospitalized for SARS-CoV-2, 361 were admitted to the participating ICUs, 257 were ventilated for more than 24 hours and 247 were included in the study. The length of stay in ICU was 21 (12-32) days and the mortality rate was 45%. Using multiple regression, risk factors for mortality were age TRANS, high serum SERO creatinine value, low mean arterial pressure, low lymphocytes count on day 0 and the absence of corticosteroid therapy during the first week of mechanical ventilation. The mortality rate of the patients who received corticosteroids was 34% and 48% for patients who did not (p = 0.01).Conclusion: In this multicenter cohort, the mortality of patients with SARS-CoV-2 pneumonia MESHD pneumonia HP treated with mechanical ventilation was high. The risk factors for mortality included age TRANS, renal and circulatory dysfunction, lymphopenia MESHD lymphopenia HP and the absence of corticosteroid therapy during the first week of mechanical ventilation. 

    Low Diaphragm Muscle Mass Predicts Adverse Outcome in Patients Hospitalized for Covid-19 Pneumonia MESHD Pneumonia HP

    Authors: Francesco Corradi; Alessandro Isirdi; Claudia Brusasco; Gregorio Santori; Marco Falcone; Luna Gargani; Chiara Romei; Greta Barbieri; Fabio Guarracino; Luigi Vetrugno; Giovanni Landoni; Francesco Forfori

    doi:10.21203/ Date: 2020-08-01 Source: ResearchSquare

    Purpose: The aim of this study was to evaluate whether measurement of diaphragm thickness by ultrasonography may be a clinically useful noninvasive method for identifying patients at risk of adverse outcomes defined as need of invasive mechanical ventilation or death MESHD. Methods: We retrospectively reviewed the records of consecutive of 77 patients with laboratory-confirmed Covid-19 infection MESHD admitted to our intermediate care unit in Pisa between March 5 and March 30, 2020, with follow up until hospital discharge or death MESHD. Logistic regression was used identify variables potentially associated with adverse outcomes and those P<0.10 were entered into a multivariate logistic regression model. Cumulative probability for lack of adverse outcomes in patients with or without low baseline diaphragm muscle mass was calculated with the Kaplan–Meier product-limit estimator.Results: The main findings of this study are that 1) patients who developed adverse outcomes had thinner diaphragm than those who did not (2.0 vs 2.2 mm, p:0.001), 2) DT and lymphocyte count were independent significant predictors of adverse outcomes, with end-expiratory DT being the strongest (-708, OR: 0.492, p: 0.018).Conclusion: Diaphragmatic ultrasound may be a valid tool to evaluate the risk of respiratory failure HP. Evaluating the need of mechanical ventilation treatment should be based not only on PaO2/FiO2, but on a more comprehensive assessment including DT because if the lungs become less compliant a thinner diaphragm, albeit free of intrinsic abnormality, may become exhausted, thus contributing to severe respiratory failure HP

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.